Document Detail


Influence of erythropoietin on arterial stiffness and endothelial function in renal transplant recipients.
MedLine Citation:
PMID:  23038220     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND/AIMS: Recent retrospective studies suggest an association of therapy with erythropoiesis-stimulating agents (ESAs) and increased mortality in renal transplant recipients (RTR). Large artery structure and function are significantly impaired in RTR which contributes to their high cardiovascular morbidity and could be altered by erythropoietin. We aimed to examine the influence of ESA therapy on large artery stiffness and endothelial function in RTR.
METHODS: 63 RTR with chronic allograft dysfunction and renal anemia were randomized to a group receiving darbepoetin alfa (Dar) and a control group (Co). At baseline and after 8 months of treatment (cumulative Dar dose 11.1 µg/kg b.w.) brachial and common carotid artery distensibility coefficients, aortic pulse wave velocity, brachial artery flow-mediated and nitroglycerin-mediated vasodilation were measured as well as the following biomarkers of vascular function: vWF, sVCAM, sICAM, E-selectin, t-PA and PAI-1.
RESULTS: 23 patients in the Dar group and 17 patients in the Co group were available for per-protocol analysis. Hemoglobin increased significantly from 10.9 to 12.6 g/dl after 8 months in the Dar group, whereas it remained stable at 11.3 g/dl in the Co group. Effects on large artery stiffness, endothelial function and biomarkers of vascular function did not differ significantly between the two groups.
CONCLUSION: Therapy with Dar during 8 months did not significantly impact parameters of large artery stiffness and endothelial function in RTR. These data suggest that therapy with erythropoietin does not deteriorate arterial stiffness and endothelial function in RTR.
Authors:
Valerie Bartels; Uta Hillebrand; Markus Kosch; Martin Hausberg; Klaus Kisters; Giovana Seno Di Marco; Stefanie Reiermann; Hermann Pavenstaedt; Detlef Lang
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-10-04
Journal Detail:
Title:  American journal of nephrology     Volume:  36     ISSN:  1421-9670     ISO Abbreviation:  Am. J. Nephrol.     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-30     Completed Date:  2013-04-09     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8109361     Medline TA:  Am J Nephrol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  355-61     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Department II of Internal Medicine, University of Cologne, DE–50937 Cologne, Germany. valerie.bartels@uk-koeln.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / drug therapy,  mortality
Brachial Artery / physiology
Endothelium, Vascular / drug effects*
Erythropoietin / administration & dosage,  analogs & derivatives*
Female
Hematinics / administration & dosage
Humans
Kidney Failure, Chronic / mortality,  surgery*
Kidney Transplantation / adverse effects*,  mortality
Male
Middle Aged
Primary Graft Dysfunction / drug therapy*,  mortality
Risk Factors
Transplantation, Homologous
Treatment Outcome
Vascular Stiffness / drug effects*
Vasodilation / drug effects,  physiology
Chemical
Reg. No./Substance:
0/Hematinics; 11096-26-7/Erythropoietin; 15UQ94PT4P/darbepoetin alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patterns of molecular motors that guide and sort filaments.
Next Document:  Pediatric Astroblastoma: A Rare Case with a Review of the Literature.